<DOC>
	<DOCNO>NCT01024595</DOCNO>
	<brief_summary>The result Phase I Safety Immunogenicity Trial Recombinant HIV-1 Tat ( ISS P-001 ISS T-001 ) indicate vaccine base recombinant Tat protein safe , well tolerate immunogenic . The present study intend extend follow-up volunteer additional 3 year evaluate persistence anti-Tat humoral cellular immune response . The result present study key design future phase II trial , particularly definition optimal schedule boost immunization . All individual ( 27 ) enrol 120-weeks observational study monitor every 24 week follow 3 year . During visit , perform within schedule indicate clinical monitoring HIV-1 infected individual , addition routine virological , hematological biochemical assessment , anti-Tat specific humoral cellular immune response evaluate .</brief_summary>
	<brief_title>Observational Study Therapeutic Study Recombinant HIV-1 TAT</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Previous participation phase I clinical trial ISS T001</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tat protein</keyword>
</DOC>